TD Cowen analyst Steve Scala lowered the firm’s price target on Bristol Myers to $67 from $80 and keeps a Market Perform rating on the shares. The company set ambitious research and development goals to increase long-term and commercial success, the analyst tells investors in a research note. However, the firm sees modest growth through 2030 for Bristol Myers.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMY:
- Most Bristol Myers de-risking pipeline data not until 2025, says Morgan Stanley
- DiaMedica appoints Ambarish Shah, Ph.D. as Chief Technology Officer
- Bristol Myers announces results from Phase 2 study evaluating BMS-986278
- Bristol Myers reports six-year results from Phase 3 CheckMate -227 trial
- Novartis sues U.S. government over price regulation, Reuters reports